• Home
  • In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"

In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"

Author List
Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE
Publication
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/259899783
Publication Year
2022
PubMed ID
35074229
Publication Title
Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE. In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?" J Thorac Oncol. 2022 02; 17(2):e12-e14.